Morphotek is one of the leading companies in the life science industry that develops novel classes of biological-based products to treat cancer, inflammation and infectious diseases. Since its founding in 2000, Morphotek has made extraordinary progress in discovering and developing monoclonal antibodies (mABs) to treat these diseases and continues to develop additional antibody products using its proprietary technologies.
Post-graduate research executed by Morphotek’s President and CEO, Dr. Nicholas Nicolaides, during his studies at Johns Hopkins Medical School was the basis for the company’s inception. It was there that Dr. Nicolaides co-invented the company's legacy technology called morphogenics. Along with the honed applications for applying morphogenics for product development refined by the company’s other co-founders, Dr. Philip Sass and Dr. Luigi Grasso, morphogenics has taken Morphotek an incredible distance in the advancement of novel pharmaceutical products and targets.
Morphotek currently has several monoclonal antibodies in clinical development for cancer and inflammatory disease. Our lead program, farletuzumab has completed a global Phase 3 clinical study testing for efficacy in patients with platinum-sensitive, relapsed ovarian cancer and 1st line non-small cell lung cancer. Morphotek’s other lead antibody monoclonal programs, amatuximab and ontuxizumab, are also being tested in clinical studies for efficacy in cancers that are positive for the target they specifically bind, namely mesothelin and endosialin/TEM-1, respectively. Mesothelin has been shown to be expressed on a variety of malignancies including pancreatic adenocarcinoma, mesothelioma, non-small cell lung carcinoma and ovarian cancers. Amatuximab is being tested in a randomized, double blind-controlled Phase 2 study in 1st line mesothelioma. Endosialin/TEM-1 is a protein whose expression is primarily restricted to tumor-associated pericytes and tumor stromal cells. Ontuxizumab is being tested in Phase 2 clinical trials across a number of different cancer types.
In the spring of 2007, Morphotek was acquired by Eisai Co. Ltd, a global health care pharmaceutical company. One of Eisai’s areas of focus is oncology, and the company is well positioned to market oncology products developed by Morphotek. Morphotek’s propriety technologies and promising antibodies, combined with Eisai’s existing research programs and infrastructure, enables the companies to work toward addressing unmet medical needs of patients, especially those with cancer and inflammatory diseases, all around the world.
Morphotek is committed to developing novel classes of biological-based products to treat cancer, inflammatory diseases and infectious diseases. The company believes that mAbs (the fastest growing segment of the biopharmaceutical market), as well as other target-specific biological-based therapies, hold the greatest promise to specifically treat and eradicate human disease.
Morphotek’s mission is to develop superior mAbs and biological therapies optimized for pharmacological activity against disease-associated targets using our suite of proprietary technologies. Morphotek will continue to achieve these goals by employing and collaborating with the best talent in industry and academia, and empowering them to achieve extraordinary results.